This clinical trial is focused on studying a type of cancer called B-cell lymphoma, which affects a part of the immune system. The trial is testing a new treatment called Epcoritamab, also known by its code name GEN3013. Epcoritamab is a solution for injection that is designed to target specific proteins on the surface of cancer cells. The purpose of the study is to find the best dose of Epcoritamab and to see how well it works in treating B-cell lymphoma.

Participants in the study will receive Epcoritamab through injections under the skin. The study will be conducted in phases, starting with a dose-escalation phase to determine the safest and most effective dose. After this, the study will expand to include more participants to further evaluate the treatment’s effectiveness. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Epcoritamab. The study will also explore whether adjusting the dose can reduce the risk of a side effect known as CRS (Cytokine Release Syndrome), which can cause symptoms like fever and fatigue.

In addition to Epcoritamab, the study may involve other medications such as Paracetamol (also known as acetaminophen), Dexamethasone, Betamethasone, Anakinra, Siltuximab, Diphenhydramine, and Tocilizumab. These medications are used to manage symptoms or side effects during the trial. The study aims to gather information over several years to understand the long-term effects and benefits of Epcoritamab for patients with B-cell lymphoma.